Clinical Trial

Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-06-30; most recent amendment 2024-01-05.
Status change: Not Yet Recruiting → Recruiting 2020-09-09
Trial Details
NCT Number NCT04459065
Lead Sponsor University of Saskatchewan
Collaborators: Western Economic Diversification Canada
Conditions Lung Cancer
Enrollment 36 participants
Start Date 2020-09-01
Primary Completion 2026-09 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2024-01-09